<div id="readability-page-1"><p>In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, with a price target of <span id="expert-recommendation-target">$7.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Folkes is a 3-star analyst with an average return of <span>2.0%</span> and a 42.07% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Collegium Pharmaceutical, and Achieve Life Sciences.</p> <p>Currently, the analyst consensus on Connect Biopharma Holdings is a Strong Buy with an average price target of $8.38.</p></div>

CNTB

SBIO

IBBQ

LABU

<p>H.C. Wainwright analyst Brandon Folkes has reiterated a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.00. Folkes, a 3-star analyst, has an average return of 2.0% and a 42.07% success rate. The consensus on CNTB is a Strong Buy, with an average price target of $8.38.</p>

Tip Ranks

Connect Biopharma

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Heron Therap

Collegium Pharma

Achieve Life Sciences

Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. Wainwright